Amorolfine

Jump to: navigation, search

{{Drugbox | Watchedfields = changed | verifiedrevid = 443386467 | IUPAC_name = (±)-(2R*,6S*)-2,6-dimethyl-4-{2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl}morpholine | image =Amorolfine.png

| tradename = | Drugs.com = International Drug Names | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ☑Y | CAS_number = 78613-35-1 | ATC_prefix = D01 | ATC_suffix = AE16 | PubChem = 54260 | DrugBank_Ref =  ☑Y | DrugBank = | ChemSpiderID_Ref =  ☑Y | ChemSpiderID = 49010 | UNII_Ref =  ☑Y | UNII = AB0BHP2FH0 | KEGG_Ref =  ☑Y | KEGG = D02923 | ChEBI_Ref =  ☑Y | ChEBI = 599440 | ChEMBL_Ref =  ☑Y | ChEMBL = 489411

| C=21 | H=35 | N=1 | O=1 | molecular_weight = 317.509 g/mol | smiles = O2[C@@H](CN(CC(C)Cc1ccc(cc1)C(C)(C)CC)C[C@@H]2C)C | InChI = 1/C21H35NO/c1-7-21(5,6)20-10-8-19(9-11-20)12-16(2)13-22-14-17(3)23-18(4)15-22/h8-11,16-18H,7,12-15H2,1-6H3/t16?,17-,18+ | InChIKey = MQHLMHIZUIDKOO-AYHJJNSGBZ | StdInChI_Ref =  ☑Y | StdInChI = 1S/C21H35NO/c1-7-21(5,6)20-10-8-19(9-11-20)12-16(2)13-22-14-17(3)23-18(4)15-22/h8-11,16-18H,7,12-15H2,1-6H3/t16?,17-,18+ | StdInChIKey_Ref =  ☑Y | StdInChIKey = MQHLMHIZUIDKOO-AYHJJNSGSA-N }}

WikiDoc Resources for Amorolfine

Articles

Most recent articles on Amorolfine

Most cited articles on Amorolfine

Review articles on Amorolfine

Articles on Amorolfine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Amorolfine

Images of Amorolfine

Photos of Amorolfine

Podcasts & MP3s on Amorolfine

Videos on Amorolfine

Evidence Based Medicine

Cochrane Collaboration on Amorolfine

Bandolier on Amorolfine

TRIP on Amorolfine

Clinical Trials

Ongoing Trials on Amorolfine at Clinical Trials.gov

Trial results on Amorolfine

Clinical Trials on Amorolfine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Amorolfine

NICE Guidance on Amorolfine

NHS PRODIGY Guidance

FDA on Amorolfine

CDC on Amorolfine

Books

Books on Amorolfine

News

Amorolfine in the news

Be alerted to news on Amorolfine

News trends on Amorolfine

Commentary

Blogs on Amorolfine

Definitions

Definitions of Amorolfine

Patient Resources / Community

Patient resources on Amorolfine

Discussion groups on Amorolfine

Patient Handouts on Amorolfine

Directions to Hospitals Treating Amorolfine

Risk calculators and risk factors for Amorolfine

Healthcare Provider Resources

Symptoms of Amorolfine

Causes & Risk Factors for Amorolfine

Diagnostic studies for Amorolfine

Treatment of Amorolfine

Continuing Medical Education (CME)

CME Programs on Amorolfine

International

Amorolfine en Espanol

Amorolfine en Francais

Business

Amorolfine in the Marketplace

Patents on Amorolfine

Experimental / Informatics

List of terms related to Amorolfine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Amorolfine (or amorolfin), is a morpholine antifungal drug that inhibits D14 reductase and D7-D8 isomerase, which depletes ergosterol and causes ignosterol to accumulate in the fungal cytoplasmic cell membranes. Marketed as Curanail, Loceryl, Locetar, and Odenil, amorolfine is commonly available in the form of a nail lacquer, containing 5% amorolfine as the active ingredient. It is used to treat onychomycosis (fungal infection of the toe- and fingernails). Amorolfine 5% nail lacquer in once-weekly or twice-weekly applications has been shown in two studies to be between 60% and 71% effective in treating toenail onychomycosis; complete cure rates three months after stopping treatment (after six months of treatment) were 38% and 46%. However, full experimental details of these trials were not available and since they were first reported in 1992 there have been no subsequent trials.[1]

It is a topical solution for the treatment of toenail infections. Systemic treatments may be considered more effective.[1]

It is approved for sale over the counter in Australia and the UK (recently re-classified to over the counter status), and is approved for the treatment of toenail fungus by prescription in other countries. It is not approved for the treatment of onychomycosis in the United States or Canada, but can be ordered from there by mail from other countries.[2]

Notes

  1. 1.0 1.1 Hywel C. Williams (2003). Evidence-Based Dermatology. Blackwell.
  2. It can readily be verified that Curanail is advertised on websites such as US Amazon.com, shipped from abroad.

Linked-in.jpg